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Abstract
In spite of intensive and increasingly successful
attempts to determine the multiple steps involved in
colorectal carcinogenesis, the mechanisms responsible
for metastasis of colorectal tumors to the liver remain to
be clarified. To identify genes that are candidates for
involvement in the metastatic process, we analyzed
genome-wide expression profiles of 10 primary color-
ectal cancers and their corresponding metastatic
lesions by means of a cDNA microarray consisting of
9121 human genes. This analysis identified 40 genes
whose expression was commonly upregulated in meta-
static lesions, and 7 that were commonly downregu-
lated. The upregulated genes encoded proteins involved
in cell adhesion, or remodeling of the actin cytoskele-
ton. Investigation of the functions of more of the altered
genes should improve our understanding of metastasis
and may identify diagnostic markers and/or novel
molecular targets for prevention or therapy of metastatic
lesions. Neoplasia (2001) 3, 395–401.
Keywords: metastasis, cDNA microarray, microdissection, colorectal cancer ( CRC ), T7 -
based RNA amplification.
Introduction
Liver metastasis is a major cause of death among patients
with colorectal cancer (CRC). Despite progress that has
been achieved with therapeutic approaches, a complete
cure awaits more effective strategies. Prevention or
effective treatment of liver metastasis will save the lives of
thousands of patients. We have attempted to identify genes
involved in metastasis of CRC to the liver in order to learn
more about the underlying mechanisms, to identify clinically
applicable diagnostic markers and preventive approaches,
and to find molecules that might be useful targets for
therapy.
Liver metastasis occurs in multiple steps that include
release of cancer cells from the primary site, intravasation to
neighboring vessels, transport to the site of metastasis
through blood flow, extravasation and/or infarction to the
distant organ, and re-growth of the invading cells with
acquisition of nutrition in the new environment. Therefore,
multiple genes must play roles. Although many investigators
have been working on this clinically important issue, the
precise mechanisms or identification of the critical genes
remains to be clarified. A number of molecules associated
with liver metastasis have been reported, but as most studies
have focused on one or a few molecules, the question of the
importance of each gene in the complex process has not
been addressed.
Because microarray technology permits analysis of
expression levels of thousands of genes in a single experi-
ment, new classifications of cancer types can now be
proposed on the basis of altered expression of multiple
genes in tumor tissues [1,2 ] . Moreover, analyses of gene
expression profiles have disclosed specific patterns that may
reflect progression of tumor cells [3,4] . Recently, two groups
detected genes responsible for metastasis of malignant
melanomas, using cDNA microarrays. One group compared
expression profiles of highly metastatic melanoma cells with
less metastatic cells established from the same cell lines [5] ;
the other analyzed expression profiles among various
melanoma cell lines and primary melanomas [6] .
Here we report identification of 47 genes whose expres-
sion was commonly altered in metastatic CRC cells to the
liver by comparing expression profiles of primary and
metastatic CRCs on a cDNA microarray containing 9121
genes. This information will be useful for clarifying the
mechanisms of liver metastasis and for discovering new
molecular targets for its diagnosis, treatment, or prevention.
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Materials and Methods
Tissue Samples and Laser Capture Microdissection (LCM)
Primary CRC tissues and corresponding metastatic foci
from liver were obtained with informed consent from 10
patients who underwent colectomy and hepatectomy in the
same operation. All of the samples were imbedded in
TissueTek OCT medium (Sakura, Tokyo, Japan) and
frozen at 808C. Later, the frozen sections were fixed in
70% ethanol for 45 seconds, stained with hematoxylin and
eosin, and dehydrated in 70:30, 50:50, and 30:70 of
ethanol:xylene for 30 seconds at each step, followed by a
final dehydration in 100% xylene for 2 minutes. Once air -
dried, the stained tissues were microdissected using a
PixCell LCM system (Arcturus Engineering, Mountain
View, CA) according to the manufacturer’s protocols.
Cancerous cells from the primary lesions and from liver
metastases were selectively microdissected (2104 cells
from each sample).
RNA Extraction and T7-Based RNA Amplification
Total RNA was extracted from each sample of laser-
captured cells into 350 l of RLT lysis buffer (QIAGEN,
Hilden, Germany). The extracted RNA was treated for 1
hour at 378C with 10 U of DNase I (Roche, Basel,
Switzerland) in the presence of 1 U of RNase inhibitor
(TOYOBO, Osaka, Japan) to remove any contaminating
genomic DNA. After inactivation at 708C for 10 minutes, the
RNA was purified with an RNeasy Mini Kit (QIAGEN)
according to the manufacturer’s recommendations. All
DNase I–treated RNA was subjected to T7-based ampli-
fication as described previously [7 ] . Three rounds of
amplification yielded 8 to 70 g of amplified RNA (aRNA)
from each sample.
Construction and Analysis of the cDNA Microarray
We had selected 9121 independent cDNA, including
some ESTs, from the UniGene database of the National
Center for Biotechnology Information. The cDNA spotted on
the microarray slides was prepared by reverse transcription
polymerase chain reaction (RT-PCR) using sets of gene-
specific primers and a mixture of commercially provided
poly A RNA (Clontech, Palo Alto, CA) as a template [7 ] .
The products were applied to electrophoresis on agarose
gels and those showing a single band of expected size
were utilized for spotting. Further sequence analyses of
randomly selected 2485 (27.2%) products from 9121
genes corroborated the complete concordance of their
cDNA sequences.
Duplicate sets of cDNA spots were used for each
analysis of expression profiles to reduce experimental
fluctuation. Three-microgram aliquots of each aRNA from
primary CRCs and metastatic lesions were labeled with
Cy5-dCTP or Cy3-dCTP, respectively (Amersham Phar-
macia Biotech, Buckinghamshire, England). Equal amounts
of Cy3- and Cy5- labeled probes were co-hybridized onto
the microarray slides. Hybridization, washing, and scanning
were performed as described previously [7 ] .
Data Analysis
The intensity of each duplicated signal was evaluated
photometrically by the Array Vision computer program
Figure 1. Representative scatter plot ( normalized ) from the cDNA microarray analysis. Amplified RNA from the primary (Cy5 - labeled ) and metastatic (Cy3 -
labeled ) lesions from case no. 101 were hybridized to the microarray slides. The y=2x line represents the cut - off border for upregulated genes, and y=2 1x is the
border for downregulated genes. The horizontal line (Cy3 ) and the vertical line (Cy5 ) are cut - off borders for reliable signal intensity. Yellow diamonds indicate
housekeeping genes, which were used for normalization of data.
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( Imaging Research, St. Catharines, Ontario, Canada) and
normalized so that the averaged Cy3/Cy5 ratio of 52
housekeeping genes was 1.0. [3,7 ] (Figure 1 ). After the
normalization of signal intensity of each spot, we excluded
data if both Cy3 and Cy5 signals were less than those of
either the Arabidopsis thaliana putative chlorophyll synthe-
tase (G4) gene or pBluescript II SK( + ) vector DNA, which
had been spotted on the microarray slides as negative
controls. The Cy3/Cy5 ratio for each gene was calculated by
averaging duplicate spots [3,7 ] . Genes whose Cy3/Cy5
ratios were greater than 2 were considered to be upregulated
in the metastatic tissues, whereas those with ratios less than
0.5 were considered to be downregulated. Finally, genes that
showed increased expression in six or more of the 10 cases
examined were selected as ‘‘frequently upregulated’’ genes,
and those that showed decreases in five or more cases were
selected as ‘‘frequently downregulated.’’ We evaluated the
significance of altered expression of the selected genes by
calculating the P values using a matched pair permutation
test as described previously [3 ] .
Quantitative RT-PCR (TaqMan-PCR)
To verify the data obtained from microarray, we carried
out quantitative RT-PCR (TaqMan-PCR) with additional
eight pairs of CRCs according to the manufacturer’s
recommendations (Applied Biosystems, Foster City, CA).
Total RNA extracted from microdissected tissues was
subjected to one round of T7-based RNA amplification
followed by cDNA synthesis using 0.5 g of random hexamer
(Roche) and SuperScript II according to the supplier’s
protocol (Life Technologies, Gaithersburg, MD). The syn-
Table 1. Number of Selected Genes.
Case ID 71 95 97 100 101 103 145 147 158 159
Up 427 286 136 560 515 311 279 492 528 583
Unchanged 899 475 1521 556 1941 1860 571 1016 700 1356
Down 19 51 270 220 51 60 48 62 50 41
Total 1345 812 1927 1336 2511 2231 898 1570 1278 1980
Figure 2. Quantitative RT -PCR analysis of three upregulated genes (A ) and three downregulated genes (B ). Relative expression in liver metastasis to primary
lesion is indicated as log2 (Metastasis /Primary ).
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Table 2. Upregulated Genes.
Frequency Average Ratio±SD P Value Accession Number UniGene Cluster Definition
8 2.8±0.9 1.56E04 U01828 167 Human microtubule - associated protein 2 (MAP2 ) mRNA;
complete cds
8 5.7±4.1 1.10E04 AJ000553 103 527 Homo sapiens mRNA for T lymphocyte–specific adaptor
protein (SH2D2A )
8 5.7±3.7 2.24E05 U73529 34 526 Human G protein–coupled receptor STRL33.1 (STRL33 )
mRNA; complete cds
7 4.7±2.0 5.33E04 M26682 1149 Human T cell translocation gene 1 (Ttg - 1 ) mRNA;
complete cds
7 3.0±1.0 4.38E05 M24594 20 315 Human interferon - inducible 56 kDa protein mRNA;
complete cds
7 4.5±1.7 1.59E05 D14520 84 728 Human mRNA for GC box binding protein BTEB2;
complete cds
7 4.4±2.1 1.36E05 J04759 183 994 Human protein phosphatase I alpha subunit (PPPIA )
mRNA; 30 end
7 5.0±3.8 1.36E03 M55172 2159 Human large aggregating cartilage proteoglycan core
protein mRNA; complete cds
7 6.6±4.7 5.87E05 Y00816 193 716 Human mRNA for complement receptor type 1
(CR1, C3b /C4b receptor, CD35 )
7 4.4±3.0 4.36E04 AB014539 15 711 H. sapiens mRNA for KIAA0639 protein; partial cds
7 5.1±2.7 1.05E04 Z29373 1757 H. sapiens gene for neural cell adhesion molecule L1
7 3.7±1.4 1.92E04 AF116238 23 723 H. sapiens pseudouridine synthase 1 (PUS 1) mRNA;
partial cds
6 3.7±1.7 1.81E04 L09749 112 494 H. sapiens ( clone F4 ) transmembrane protein
mRNA sequence
6 4.2±2.3 3.24E03 M17254 45 514 Human erg2 gene encoding erg2 protein; complete cds
6 2.5±0.5 3.70E03 U77086 117 367 Human organic cation transporter 1 (hOCT1 ) mRNA;
complete cds
6 4.7±2.8 5.24E04 U97519 16 426 H. sapiens podocalyxin - like protein mRNA; complete cds
6 4.4±2.1 2.82E05 D88460 288 830 H. sapiens mRNA for N -WASP; complete cds
6 5.1±3.2 2.94E05 AF062075 49 587 H. sapiens leupaxin mRNA; complete cds
6 4.8±2.9 5.18E05 X77197 199 250 H. sapiens mRNA for chloride channel
6 4.4±3.0 1.55E04 X12830 193 400 Interleukin 6 receptor
6 4.8±3.0 1.46E03 X71355 100 001 H. sapiens mRNA for sodium phosphate transport system 1
6 5.2±3.4 5.11E04 L20431 79 391 H. sapiens Huntington disease–associated protein (HD )
mRNA; complete cds
6 2.5±0.3 1.39E04 L41351 75 799 H. sapiens prostasin mRNA; complete cds
6 3.3±1.1 1.38E03 U90441 3622 Human prolyl 4 - hydroxylase alpha ( II ) subunit mRNA;
complete cds
6 4.0±1.4 1.89E04 AF007216 5462 H. sapiens sodium bicarbonate cotransporter (HNBC1 )
mRNA; complete cds
6 3.1±0.7 3.28E05 U10689 37 108 Human MAGE-5a antigen (MAGE5a ) gene; complete cds
6 5.4±1.7 1.13E04 M35296 121 521 Human tyrosine kinase arg gene mRNA
6 3.7±1.9 3.07E06 M86752 75 612 Human transformation - sensitive protein ( IEF SSP 3521 )
mRNA; complete cds
6 5.0±2.3 1.06E04 X73502 84 905 H. sapiens mRNA for cytokeratin 20
6 3.5±1.3 1.06E04 U68723 211 773 Human checkpoint suppressor 1 mRNA; complete cds
6 3.5±1.5 1.14E04 X52151 88 251 H. sapiens arylsulphatase A mRNA; complete cds
6 5.0±2.8 1.23E03 AF056929 50 550 H. sapiens sarcosin mRNA; complete cds
6 3.0±1.3 3.60E06 X98801 74 617 H. sapiens mRNA for dynactin
6 4.5±2.2 2.66E05 W25099 41 997 ESTs, highly similar to alpha -1B -glycoprotein (H. sapiens )
6 4.1±2.2 2.53E04 AF151351 274 287 H. sapiens pyrroline 5 - carboxylate reductase isoform
(P5CR2 ) mRNA; complete cds
6 3.5±1.1 8.38E05 X99688 154 658 H. sapiens mRNA from TYL gene
6 3.3±1.0 1.95E04 AF044953 31 547 H. sapiens NADH:ubiquinone oxidoreductase PGIV subunit
mRNA; nuclear gene encoding mitochondrial protein
6 3.3±1.0 1.22E05 AL133558 55 209 H. sapiens mRNA; cDNA DKFZp434K0514 ( from clone
DKFZp434K0514 ); partial cds
6 4.6±2.4 1.39E04 M20543 1288 Human skeletal alpha -actin gene; complete cds
6 3.7±1.5 1.70E04 AL133068 62 880 H. sapiens mRNA; cDNA DKFZp434B0717 ( from clone
DKFZp434B0717 )
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thesized cDNA was diluted and used as template for
amplification on ABI Prism 7700 Sequence Detection
System (Applied Biosystems). A set of primers and a
TaqMan probe for a housekeeping gene, 2-microglobulin
(Applied Biosystems), were used as endogenous control.
Sequences of primers and probes of genes selected for
verification were as follows: microtubule-associated protein
2 (MAP2) ( forward) 50 -TCGAATCTCCTCAGCTTGCC-30,
( reverse) 50 -CACAAGCCCTGCTTAGCGA-30, (probe) 50 -
Fam-CTTTGGCTGAGGATGTCACTGCTGCA-Tamra-30;
N-WASP (forward) 50 -ACTGTTAGACCAGATACGACAG-
GGT-30, ( reverse) 50 -TGCAGGTGTTGGTGGTGTAGA-30,
(probe) 50 -Fam-TCCAACTAAAATCTGTGGCTGATGGC-
CA-Tamra-30; neural cell adhesion molecule L1 (NCAM-
L1) ( forward) 50 -GTCTGAACAGTTGTCTTCCTCAGC-30,
( reverse) 50 -CAAACTTTCAAAGTCACGGTGTATTT-30,
(probe) 50 -Fam-TCCTCCCGCCCCCACTTGG-Tamra-30;
S3 ribosomal protein ( forward) 50 -TGAGCATTGTGGAAC-
CCAAA-30, ( reverse) 50 -GCTTCCCACCCTTCTGTTCTG-
30, (probe) 50 -Fam-ATGAGATACTGCCCACCACCCCCA-
TC-Tamra-30; caltractin ( forward) 50 -AGCACCTGCCATT-
TTGCC-30, ( reverse) 50 -GTTCTGTGTTTGTGGATATGT-
GGAA-30, (probe) 50 -Fam-TGCATCGTTTCCCTCGT-
CATGCA-Tamra-30; EST (BC005071) ( forward) 50 -TC-
AGTTATCTCCAGAGCCATTTCA-30, ( reverse) 50 -GACT-
GGATAATAAACCACCTCTGACA-30, (probe) 50 -Fam-CC-
TTTAGAGTGAGTCACATGCAGGGAGTGTG-Tamra-30.
Comparative CT Method was employed to determine the
expression ratio of each gene (Applied Biosystems).
Results
Isolation of Primary CRCs and Corresponding Metastatic
Lesions by LCM
To obtain precise expression profiles of primary versus
metastatic cancer cells, it was essential to collect pure
populations of each type. Therefore, we employed LCM to
avoid contamination by non-cancerous cells. The proportion
of cancer cells that selected by this procedure was estimated
to be >95%, as determined by microscopic visualization
(data not shown).
To investigate further the amount of hepatocyte contam-
ination in the microdissected metastatic lesions, we exam-
ined the signal intensity of the albumin gene, which is not
expressed in colon cancer cells. When hepatocytes were
selectively dissected from a non-cancerous liver specimen,
the ratio of the average signal intensity of the albumin gene to
that of the GAPDH gene was approximately 53.7, whereas
the ratio in microdisssected metastatic cells was 0.14.
Consequently, the proportion of contaminating hepatocytes
among the dissected cancer cells we analyzed was
estimated to be less than 0.3%. Because the cut -off value
we applied in this study was higher than the signal intensity of
the albumin gene, we considered that contamination by
hepatocytes would have little effect on our analysis of
expression profiles.
Identification of Genes Expressed Differently in
Metastasized Versus Primary CRCs
The numbers of selected genes in each expression
category, as judged by their ratios of signal intensity of
metastatic to primary cancer tissues, are summarized in
Table 1; a representative scatter plot is shown in Figure 1.
Given the inevitable diversity among individual tumors and
the variety of factors that could affect gene expression, we
selected for further study only the genes whose expression in
metastatic tissue was elevated more than two- fold in six or
more, or reduced to less than half in five or more, of the 10
cases examined. In this manner, we identified 40 genes that
commonly showed elevated expression in the metastatic
lesions and seven genes, two of them ESTs, that revealed
reduced expression (Tables 2 and 3). These commonly
altered genes corresponded to about 0.44% and 0.08%,
respectively, of the 9121 genes analyzed. The selected
group included genes known to be involved in cell adhesion,
or remodeling of the actin cytoskeleton. Among them, three
[MAP 2, T lymphocyte–specific adaptor protein (SH2D2A),
and G protein–coupled receptor STRL33.1 (STRL33) ] were
upregulated in 8 of 10 cases. Among the genes showing
reduced expression, the HNK-1 gene was downregulated in
six cases, while others, including genes encoding autono-
mously replicating sequence (ARS), caltractin, S3 ribosomal
protein, and 40S ribosomal protein S19, were downregulated
in five cases.
Validation of Expression Differences by Quantitative PCR
To verify the result of microarray, we selected three
upregulated genes (MAP 2, N-WASP, and NCAML1) and
three downregulated genes [EST (BC005071), S3 riboso-
mal protein, and caltractin ] , and performed quantitative RT-
PCR using additional eight pairs of CRCs. As shown in
Table 3. Downregulated Genes.
Frequency Average Ratio±SD P Value Accession Number UniGene Cluster Definition
6 0.3±0.2 .0134 AF033827 155 553 Homo sapiens HNK-1 sulfotransferase mRNA; complete cds
6 0.3±0.1 .0142 BC005071 332 382 ESTs
5 0.3±0.2 .0135 S42658 252 259 S3 ribosomal protein ( human, colon, mRNA, 826 nt )
5 0.3±0.2 .0061 X72964 82 794 H. sapiens mRNA for caltractin
5 0.4±0.1 .0142 X99977 103 505 Human autonomously replicating sequence (ARS) mRNA
5 0.3±0.1 .0227 M81757 298 262 40S ribosomal protein S19
5 0.4±0.1 .0318 N54851 108 222 ESTs
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Figure 2, the frequencies of elevated expression of upregu-
lated genes (6/8 cases of MAP 2, 5/8 of N-WASP, and 7/8
of NCAML1), and those of reduced expression of down-
regulated genes (5/8 cases of S3 ribosomal protein, 3/8 of
caltractin, and 3/8 of the EST) were almost in good
agreement with the data of microarray (8/10 cases of MAP
2, 6/10 of N-WASP, 7/10 of NCAML1, 5/10 of S3 ribosomal
protein, 5 /10 of caltractin, 6/10 of the EST).
Discussion
Many molecular events, some involving acquisition of
malignant properties, are involved in carcinogenesis.
Among the various steps in the progression of cancer,
metastasis is the one that critically affects the prognosis of
individual patients. It is clear that multiple gene products
must play essential roles. Consistent with that view, our
comparison of gene expression profiles between primary
CRCs and corresponding metastatic lesions disclosed
altered expression of at least 47 genes among the 9121
genes examined.
A similar study, using oligonucleotide microarrays to
screen melanoma cells representing different metastatic
phenotypes but established from the same cell lines,
disclosed a number of genes that might be associated with
metastasis [5 ] . However, because the experiments involved
injection of melanoma cells into the murine spleen and
resection of the resulting tumors, genes involved specifically
in invasion or intravasation theoretically would not be
detected; the genes identified in the study were in fact much
fewer than we detected in ours. A separate group also
analyzed expression of various melanoma cell lines and
tissues by microarray, and their data demonstrated expres-
sion profiles associated with different malignant properties
such as growth, local invasion, and, of course, metastasis
[6 ] . We chose a combined strategy; i.e., a direct comparison
between primary cancer tissue and a metastatic lesion from
the same patient, based on the hypothesis that the properties
of primary and metastatic cells are different and/or that the
proportion of cells with high metastatic potential is increased
in metastatic foci. However, the genes selected in our study
may include not only those representing the nature of cancer
cells but also genes that were affected by metastasis as
secondary events, e.g., by responding to changes in the local
environment ( liver versus colon). Investigations are ongoing
to clarify the importance of the candidate genes and their
actual roles, if any, in liver metastasis.
The commonly upregulated genes identified in our
experiments included several whose products are associ-
ated with the cytoskeleton, e.g., MAP2, N-WASP, and
dynactin. N-WASP, being tightly regulated by multiple
signals including CDC42 and phosphatidylinositol (4,5) -
biphosphate (PIP2), plays a role in the remodeling of the
actin cytoskeleton [8] ; dynactin, as a complex with
cytoplasmic dynein, interacts directly with microtubules to
form transporter vesicles and organelles [9 ] . These data
suggest that microtubules and molecules involved in
remodeling of the cytoskeleton may play crucial roles in
metastatic events by changing cellular morphology during
intra- and extravasation.
In our experiments, genes associated with cellular
adhesion such as NCAML1, podocalyxin- like protein, and
leupaxin were also upregulated; others have reported a
significant increase in NCAM expression in aggressive
melanomas with high metastatic potential [10] . Leupaxin
contains three LD motifs, which have been implicated in
binding to cytoplasmic protein tyrosine kinase and vinculin
[11] ; this protein may be engaged in a signal transduction
pathway associated with cell adhesion. The combined data
underscore the importance of adhesion molecules in the
process of metastasis. Moreover, genes with elevated
expression may be good candidates to serve as metastatic
markers for clinical diagnosis and are potential molecular
targets for treatment and/or prevention of metastases.
Genes that were commonly downregulated in the
metastatic lesions studied here included HNK-1 and
caltractin. The HNK-1 epitope, a cell surface carbohydrate,
has been implicated in cell - to-cell and cell - to-extracellular
matrix adhesion [12] ; its expression was suppressed in
liver metastases of melanomas [10] . Moreover, HNK-1
expression has shown a positive correlation with differ-
entiation of prostate tumors and survival of patients with
prostate cancer [13] . These data suggest an anti -
metastasizing potential of HNK-1. Caltractin, for its part,
shows a strong similarity in amino acid sequence to CDC31
— a protein that is required for proper duplication and
segregation of the centrosome, a major microtubule-
organizing center [14] . Therefore, reduced expression of
the caltractin gene may contribute to the malignant nature of
cancer cells by abrogating duplication.
In addition to known and well -characterized genes, the
lists reported here contain various ESTs and uncharacter-
ized genes. Investigation of their functions may shed light on
the detailed mechanisms of liver metastasis and yield clues
for identification of more reliable and sensitive diagnostic
markers and more effective therapeutic modalities.
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